Cowen downgraded AcelRx Pharmaceuticals (NASDAQ: ACRX) from Outperform to Neutral and removed their $14 price target in light of recent ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE